000963 Huadong Medicine
- 29.48
- +0.83+2.90%
Huadong Medicine News
Express News | Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials
Huadong Medicine (000963.SZ): HDM1002 is currently in Phase II clinical trials in China.
Huadong Medicine (000963.SZ) stated on the investor interaction platform on July 5th that the company will choose the overseas clinical development path according to the project situation in the future. HDM1002 is currently in phase II clinical research in China.
Huadong Medicine (000963.SZ): Baoling Health has products such as "Good Elements PQQ Collagen Peptide Drink".
On July 5th, Gelunhui reported that Huadong Medicine (000963.SZ) stated on their investor interaction platform that their subsidiary, Bailin Health, has products such as 'Shanyao PQQ Collagen Peptide Drink.'
Huadong Medicine's Unit Gets US FDA's Nod to Trial Tumor Drug
Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, will conduct Phase I clinical trials on HDM2005 for injection in the US after receiving the approval of the country's Foo
Investors Don't See Light At End Of Huadong Medicine Co., Ltd's (SZSE:000963) Tunnel
Huadong Medicine Co., Ltd's (SZSE:000963) price-to-earnings (or "P/E") ratio of 16.7x might make it look like a buy right now compared to the market in China, where around half of the companies have P
Huadong Medicine (000963.SZ): HDM2005, the injectable drug used in China and the United States, has obtained the approval of FDA's new drug clinical trial.
On July 1st, Gelunhui reported that Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongmei Huadong"), received a notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for injection HDM2005 drugs declared by Zhongmei Huadong has been approved by the FDA and can conduct phase I clinical trials in the United States. Injected HDM2005 is a type 1 new biopharmaceutical with global intellectual property rights developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It is a targeted receptor tyrosine.
Express News | Huadong Medicine - Hdm1002 Phase Ib Trial Shows Significant Weight Loss in 100Mg or Higher Dose Group
Express News | Huadong Medicine Co Ltd - Hdm1002 Significantly Reduces Postprandial Blood Glucose Levels
Express News | Huadong Medicine Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist Hdm1002
Huadong Medicine (SZSE:000963) Shareholders Have Endured a 24% Loss From Investing in the Stock Three Years Ago
Investors can earn very close to the average market return by buying an index fund. But in any given year a good portion of stocks will fall short of that. Unfortunately for investors in Huadong Med
Huadong Medicine: Q1 report in 2024 (English version)
Huadong Medicine: 2023 Annual Report (English Version)
Huadong Medicine Gets Regulatory OK to Test Tumor Drug
Huadong Medicine (SHE:000963) will conduct clinical trials on HDM2005 for injection after receiving approval from China's National Medical Products Administration, according to the company's disclosu
Huadong medicine (000963.SZ): Approval obtained for clinical trial application of injection HDM2005.
On June 4th, Gelonhui reported that Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong"), recently received the Drug Clinical Trial Approval Notice (Notice No.: 2024LP01313) issued by the National Medical Products Administration (NMPA). The clinical trial application for injection HDM2005 submitted by Zhongmei Huadong was approved. Injection HDM2005 is a category 1 new biopharmaceutical developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. with global intellectual property rights, and is a targeted receptor drug.
Huadong Medicine (000963.SZ): Currently, the company's industrial microbiology sector has produced Meike Health's vitamin K2 products.
Huadong Medicine (000963.SZ) stated on its investor interaction platform on June 4th that its industrial microbiology sector currently has Mikii Health's vitamins K2 products in production. Currently, this business has a relatively small impact on the company as a whole.
Private Companies Invested in Huadong Medicine Co., Ltd (SZSE:000963) Copped the Brunt of Last Week's CN¥3.4b Market Cap Decline
Key Insights Significant control over Huadong Medicine by private companies implies that the general public has more power to influence management and governance-related decisions A total of 2 inves
Huadong Pharmaceutical (000963.SZ) 2023 equity distribution: 5.8 yuan for every 10 shares. The share registration date is May 27
Huadong Pharmaceutical (000963.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Huadong Pharmaceutical (000963.SZ): The wholly-owned subsidiary received a notice of acceptance of drug registration
Gelonghui, May 12, 丨 Huadong Pharmaceutical (000963.SZ) announced that on May 11, 2024, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “China-US Huadong”), a wholly-owned subsidiary of the company, received the “Notice of Acceptance” (acceptance numbers: CXHS2400040, CXHS2400041) issued by the National Drug Administration (NMPA), and Meifertinib tablets (Mifertinib Tablets) were declared by China and US as the applicant for use in the epidermal growth factor receptor (EGFR) 21 Exon number L858R
Huadong Pharmaceutical (000963.SZ): Diabetes Indications have now completed the Phase III clinical study and all subjects have been enrolled. It is expected that the main endpoint data will be obtained in Q4 2024
Gelonghui, May 11 | Huadong Pharmaceutical (000963.SZ) said on the interactive platform that the company's simeglutide injection project is progressing according to plan. All subjects of the Phase III clinical study on diabetes indications have now been enrolled, and it is expected that the main endpoint data will be obtained in Q4 2024.
East China Pharmaceutical (000963.SZ): The company's industrial microbiology focuses on two major business scenarios: the application of synthetic biology technology systems and biomedical innovation and development
Gelonghui, May 11 | Huadong Pharmaceutical (000963.SZ) said on an interactive platform that the company has been deeply involved in the field of industrial microbiology for more than 40 years and has a deep industrial base and industrial transformation capabilities. The company established a subsidiary Huida Biotech in 2020 as the company's industrial microbial technology innovation platform, and acquired Nannong Dongyao in April 2023 to quickly enter the field of animal protection. The company's industrial microbiology focuses on the two major business scenarios of synthetic biology technology system application and biomedical innovation and development. It has formed a gap in the four major fields of xRNA, specialty APIs & intermediates, health & biomaterials, and animal health
Analysis
Price Target
No Data
